Stephen D Smith, MD
University of Washington
Seattle Cancer Care Alliance
825 Eastlake Avenue East, G3-200
Seattle, WA 98109-1023
Specialty / Expertise
- Specialized care of lymphoma patients
- Autologous stem cell transplantation
- Inpatient care of patients with hematologic malignancies
- Developing novel, targeted therapies for the treatment of Non-Hodgkin and Hodgkin lymphomas
- Identification of clinical and biologic prognostic factors in lymphoma
Current Research Projects
Oprozomib +/- Rituximab: Response-Adapted Therapy in Untreated Waldenström’s Macroglobulinemia
Funding Source: NCCN Grant, 2014 - 2016
A collaborative clinical trial with correlative studies in conjunction with the University of Utah Huntsman Cancer Institute.
Dr. Smith graduated from Stanford University with a bachelor's degree in Biological Sciences in 1997. He then completed a medical degree at the University of Southern California Keck School of Medicine in 2002, and continued training with internship and residency at the Los Angeles County/USC Hospital. He completed his internal medicine residency in 2005. Afterwards, he moved to Cleveland Ohio for fellowship in hematology and medical oncology at the Cleveland Clinic Foundation, finishing subspecialty training in 2008.
Smith, S and Sweetenham, J. Iodine 131 tositomomab in the treatment of non-Hodgkin’s lymphoma. (Review) Future Oncology 2007;3(3): 255-262
Smith SD, Bolwell BJ, Sweetenham JW et al. Autologous stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplantation 2007;40(3):239-43.
Smith SD, Bolwell BJ, Sweetenham JW et al. High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplantation (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL. Leukemia and Lymphoma 2009;50(10):1625-31.
Smith SD, Bolwell B, Rybicki L, Kang T, Dean R, Advani A, Thakkar S, Sobecks R, Kalaycio M, Pohlman B, Sweetenham J. Comparison of outcomes after autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma according to prior therapy with rituximab. Bone Marrow Transplantation 2010 May 17 (epub ahead of print)
b, Hsi E, Bolwell B, Pohlman B, Dean R, Effinger M, Maggiotto A, Sweetenham J. Validation of the Mantle Cell Lymphoma International Prognostic Index (MIPI): A Single-Center Retrospective Analysis [Letter]. American Journal of Hematology. Am J Hematol. 2010 Jun;85(6):454-6.
Smith SD, Dean R, Pohlman, B, Sobecks R, Copelan E, Andresen A, Bolwell B, Jocelyn C Maragulia, Jill M Vanak, ACNP, Moskowitz CH, Sweetenham J, and Moskowitz A. Autologous Stem Cell Transplant for Early Relapsed/Refractory Hodgkin Lymphoma: Results from Two Transplant Centers. Br J Haematol. 2011 May;153(3):358-63.
Smith S., Chen A., Spurgeon S., Okada C., Fan G., Dunlap J., Braziel R., Maziarz R. Diffuse Large B-Cell Lymphoma in Adults aged 75 and Older: A Single Institution Analysis of Cause-specific Survival and Prognostic Factors. Accepted 8/19/13, in press. Therapeutic Advances in Hematology
Smith, S and Sweetenham, J. Studying Survival in HL: All for One, or One for All? Why Methodology Matters. (Editorial) Oncologist. 2009 Aug;14(8):814-5.
Smith, SD and Sweetenham, J. Intensive Therapies for Mantle Cell Lymphoma: Time for a Disease-Specific Approach? (Commentary) Leukemia and Lymphoma March 2010; 51:357-359.
Smith, SD and Gupta, A. Prognosis and Risk Stratification of Mantle Cell Lymphoma in the Modern Era. Leading Article, Current Medical Literature- Leukemia and Lymphoma (Review). Vol 18 Number 2, 2010
Last updated: February 2014